🇺🇸 FDA
Patent

US 10875903

Bifunctional fusion proteins to inhibit angiogenesis in tumor microenvironment and to activate adaptive immune responses and the genes and uses thereof

granted A61KA61K38/00A61P

Quick answer

US patent 10875903 (Bifunctional fusion proteins to inhibit angiogenesis in tumor microenvironment and to activate adaptive immune responses and the genes and uses thereof) held by CHINA PHARMACEUTICAL UNIVERSITY expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CHINA PHARMACEUTICAL UNIVERSITY
Grant date
Tue Dec 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K38/00, A61P, A61P35/00, A61P37/02